Although it is one of the largest studies concerning the potential of HMGB1 as a predictive and monitoring biomarker in lung cancer, the number of patients was still deemed too low to sensibly split the cohort into a discovery and validation sample while keeping statistical power at an appropriate level. This evidence concerns the gene HMGB1 and lung carcinoma.